August 08, 2025

Neuroimaging Study Reveals SuperAging Brain Traits

Superagers aged 80 years and older demonstrate a unique neurobiological profile associated with successful aging: preserved memory and distinct brain anatomy, including thicker cortical regions and lower tau pathology.

Conexiant

August 08, 2025

Mental Health Risk High in Patients with Hidradenitis Suppurativa

Hidradenitis suppurativa is associated with increased risks of depression and anxiety across all treatment levels, highlighting the importance of proactive psychiatric screening in dermatologic care.

Conexiant

August 01, 2025

Dogs' Noses Detect Parkinson’s Disease

Trained dogs are able to sniff out disease-positive sebum samples

The Pathologist

August 08, 2025

Unprompted Speech Changes Found in ME/CFS

Nearly 1 in 10 individuals with myalgic encephalomyelitis/chronic fatigue syndrome reported voice or speech changes in a recent survey, despite not being directly asked about these symptoms.

Conexiant

August 07, 2025

Flu Treatment Linked to Lower Neuropsychiatric Risk in Pediatric and Adolescent Patients

Subgroup analyses demonstrated a greater reduction in neurologic events than psychiatric events, though the reduction in psychiatric events was not statistically significant.

Conexiant

August 06, 2025

Psilocybin Control Groups Show Lower Depression Gains

Researchers assess whether differences in control group outcomes across antidepressant trials reflect methodological variability, patient expectations, or limitations in blinding effectiveness.

Conexiant

August 06, 2025

UV Light Linked With Lower Respiratory Infection Rates 

Researchers found that germicidal UV light modestly reduced total respiratory infections in long-term care facilities for older adults.

Conexiant

August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant

August 06, 2025

Not All Problematic Internet Use Is Equal, Expert Argues

Not all screen time is created equal. That’s the message from a recent editorial, which challenges the idea that all forms of problematic internet use led to the same cognitive consequences.

Conexiant